NCT00127127 2022-09-13
MK-0683-029
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
16 trialsNCT00858234 2021-04-09
MK-0683-098
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00642954 2020-11-18
MK-0683-074
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00109109 2019-11-14
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00667082 2017-11-22
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
Phase 1 Completed
NCT00750178 2017-04-07
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00423449 2016-02-04
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00127140 2015-09-28
A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00479232 2015-09-21
Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00632931 2015-07-30
A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00111813 2015-05-21
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00127101 2015-04-21
An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00771472 2015-04-21
Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00424775 2015-04-20
A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00791011 2014-03-05
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Amgen
Phase 1 Completed
NCT00106626 2009-04-22
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
Merck Sharp & Dohme LLC
Phase 1 Completed